The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small-molecule REV-ERB agonist | Not a hormone or natural product |
| Primary targets | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian and metabolic regulation |
| Appearance | White to off-white solid | Typical for purified research samples |
| Solubility | Soluble in DMSO and ethanol; low water solubility | Laboratory solubility depends on solvent and purity |
| Common synonyms | SR9009; Stenabolic | Stenabolic is a colloquial name, not a formal chemical name |
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
Feltenstein then took control of Thomas's care, even though he did not have admitting rights at St. Vincent's. The hospital's senior brain specialist, C. G. Gutierrez-Mahoney, was not called to examine Thomas until the afternoon of 6 November, some 36 hours after Thomas's admission. Caitlin, having flown from Britain, arrived at the hospital the following morning, by which time a tracheotomy had been performed. Her first words are reported to have been, "Is the bloody man dead yet?" Permitted to see Thomas for a short time, she returned, drunk, in the afternoon and made threats to John Brinnin. Feltenstein had her put into a straitjacket and committed to the River Crest Sanitarium. It is now believed that Thomas had been suffering from bronchitis, pneumonia, emphysema and asthma before his admission to St Vincent's. In their 2004 paper, Death by Neglect, D. N. Thomas and former GP Principal Simon Barton disclose that Thomas was found to have pneumonia when he was admitted to hospital in a coma. Doctors took three hours to restore his breathing, using artificial respiration and oxygen.
=== Projects === Focke-Wulf 1000x1000x1000 – series of bomber designs, 1944. Focke-Wulf Project I – single-seat jet fighter, 1943. Focke-Wulf Project II Focke-Wulf Project III Focke-Wulf Project VII "Flitzer" – fighter project, 1944. Focke-Wulf Project VIII – turboprop powered fighter-bomber project, also designated Fw 281 Focke Rochen – 1950s VTOL fighter project Focke-Wulf Super Lorin – Ramjet-rocket combo powered fighter Focke-Wulf Fw 354 Triebflügel – tail-sitter VTOL interceptor design Focke-Wulf TO Project Focke-Wulf Volksjäger – rocket-powered interceptor fighter project Focke-Wulf VTOL Project
=== Sound transducers === Graphene's light weight provides relatively good frequency response, suggesting uses in electrostatic audio speakers and microphones. In 2015 an ultrasonic microphone and speaker were demonstrated that could operate at frequencies from 20 Hz–500 kHz. The speaker operated at a claimed 99% efficiency with a flat frequency response across the audible range. One application was as a radio replacement for long-distance communications, given sound's ability to penetrate steel and water, unlike radio waves.
== Further reading == Moses HL, Roberts AB, Derynck R (July 2016). "The Discovery and Early Days of TGF-β: A Historical Perspective". Cold Spring Harbor Perspectives in Biology. 8 (7) a021865. doi:10.1101/cshperspect.a021865. PMC 4930926. PMID 27328871.
=== Rheumasurgery === Rheumasurgery (or rheumatoid surgery) is a subfield of orthopedics occupied with the surgical treatment of patients with rheumatic diseases. The purpose of the interventions is to limit disease activity, soothe pain and improve function. Rheumasurgical interventions can be divided in two groups. The one is early synovectomies, that is the removal of the inflamed synovia in order to prevent spreading and stop destruction. The other group is the so-called corrective intervention, i.e. an intervention done after destruction has taken place. Among the corrective interventions are joint replacements, removal of loose bone or cartilage fragments, and a variety of interventions aimed at repositioning and/or stabilizing joints, such as arthrodesis.
Sources: en.wikipedia.org
=== Aerogel production === Supercritical carbon dioxide is used in the production of silica, carbon and metal based aerogels. For example, silicon dioxide gel is formed and then exposed to sCO2. When the CO2 goes supercritical, all surface tension is removed, allowing the liquid to leave the aerogel and produce nanometer sized pores.
Wagner described the necessity of adaptation from the source material and said that the 1995 film's attempt to directly replicate the comic's motorcycle was unable to steer because the tyres were too large. Garland and VFX supervisor Jon Thum began developing the Slo-Mo concept sequences in 2009 during filming for Never Let Me Go. They experimented with an effect to replicate the visual effects of hallucinogenic drugs to see how long it could be used before it distracted the viewer from the story or action sequence. They continued to develop and modify the effect until the end of post-production, tweaking colours, colour saturation, image framing and camera motion. Slo-Mo scenes also feature a rainbow colour scheme and sparkle highlights to create an unreal and otherworldly effect. The filmmakers experimented with blood bags, prosthetics, shooting real bullets, and compressed air to see the effect of direct body hits in slow motion. In the finished film, compressed air was used to create impact ripples on flesh. Garland said the concept was inspired by nature documentaries that used high-speed photography to capture animals in slow motion. He said, "You see a whale or a shark breach the water ... then you'd stop thinking about the animal and you get transfixed by ... how water droplets connect and touch against each other. Somehow like a real [drug] trip, sort of stepping outside it but staying attached at the same time." He questioned whether the technique could be used with violence to make it purely aesthetic.
== De-adenylylators == De-AMPylation is the reverse reaction in which the AMP molecule is detached from the amino acid side of a chain protein. There are three known mechanisms for this reaction. The bacterial GS-ATase (GlnE) encodes a bipartite protein with separate N-terminal AMPylation and C-terminal de-AMPylation domains whose activity is regulated by PII and associated posttranslational modifications. De-AMPylation of its substrate AMPylated glutamine synthetase proceeds by a phosphorolytic reaction between the adenyl-tyrosine of GS and orthophosphate, leading to the formation of ADP and unmodified glutamine synthetase. SidD, a protein introduced in the host cell by the pathogenic bacteria Legionella pneumophila, de-AMPylates Rab1 a host protein AMPylated by a different Legionella pneumophila enzyme, the AMPylase SidM. Whilst the benefit to the pathogen of introducing these two antagonistic effectors in the host remains unclear, the biochemical reaction carried out by SidD involves the use of a phosphatase-like domain to catalyse the hydrolytic removal of the AMP from tyrosine 77 of the host's Rab1. In animal cells the removal of AMP from threonine 518 of BiP/Grp78 is catalysed by the same enzyme, FICD, that AMPylates BiP. Unlike the bacterial GS-ATase, FICD carries out both reactions with same catalytic domain.
== Further reading == Quammen, David, "The Sobbing Pangolin: How a threatened animal may be linked to the [Covid-19] pandemic's beginnings", The New Yorker, 31 August 2020, pp. 26–31. "More field research is needed [...]. More sampling of wild animals. More scrutiny of genomes. More cognizance of the fact that animal infections can become human infections because humans are animals. We live in a world of viruses, and we have scarcely begun to understand this one [ COVID-19 ]. (p. 31.)
== Pets == Wheatgrass is also cultivated for feeding to pet cats. Wheatgrass, along with shoots of other common grains such as oats, rye and barley, is sold for this purpose, including under the name cat grass. Many cats enjoy eating grass and wheatgrass is considered safe and healthy for them. It may provide nutrients and improve digestion by adding fiber to the diet. Eating wheatgrass may also provide mental stimulation. However, it is recommended to limit the quantity allowed, to avoid indigestion.
Sources: en.wikipedia.org
It is a synthetic research compound that activates REV-ERB nuclear receptors. It is not an approved drug or dietary supplement. Most information comes from cell and animal studies.
It binds REV-ERBα and REV-ERBβ and changes transcription of metabolic genes. This can affect circadian rhythm, lipid use, and mitochondrial function. The full downstream effects are still under study.
No. Some rodent studies show increased endurance, but controlled human trials are lacking. Claims about human performance are not established by published evidence.
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.